Amgen Q2 sales in Enbrel and Otezla bounce back quarter-over-quarter amid ongoing year-over-year headwinds

Earnings
โดย Seeking Alpha·US·Read original
Summary · why it matters

Amgen's second-quarter sales for Enbrel and Otezla rebounded from the previous quarter, even as both products continued to face year-over-year declines. The company reported overall Q2 results that beat expectations, prompting it to raise its full-year 2026 revenue guidance to a range of $38.2 billion to $39.4 billion and non-GAAP earnings per share guidance to $22.30 to $23.50. The improved outlook comes as Amgen prepares for a chief financial officer transition.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Amgen Inc
AMGN
▲ PositiveCapitalrelevance

Q2 results beat expectations and full-year guidance raised

© 2026 MarketDXNews